{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.98","upperLimit":"45.66","value":"35.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.","dispersionType":"90% Confidence Interval","groups":[{"description":"Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)","id":"OG000","title":"Arm C (Safety/Efficacy Dose Level 2)"}],"paramType":"NUMBER","populationDescription":"All 67 patients on Arm C (Safety and Efficacy at Dose Level 2) were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From start of post-induction therapy for up to 10 years","title":"Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)","type":"PRIMARY","unitOfMeasure":"percentage probability"}